Vertex Pharmaceuticals Inc logo

VRTX - Vertex Pharmaceuticals Inc Share Price

$231.91 6.4  2.8%

Last Trade - 19/01/21

Large Cap
Market Cap £44.27bn
Enterprise Value £40.16bn
Revenue £4.40bn
Position in Universe 189th / 6566
Unlock VRTX Revenue
Relative Strength (%)
1m -3.94%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -24.2%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
580.4 1,032 1,702 2,489 3,048 4,163 6,150 6,947 +48.3%
+25.2 +109 +128.9 +10.9
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 30 September 2020, VertexPharmaceuticals Incorporated revenues increased 66% to$4.58B. Net income increased from $593.6M to $2.11B.Revenues reflect United States segment increase of 77% to$3.62B, Europe` segment increase of 44% to $766.4M. Netincome benefited from Derivatives - Hedging - Gain/Lossincrease from $6.8M (expense) to $16.2M (income), Interestexpense decrease of 5% to $41.9M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for VRTX
Graphical History


VRTX Revenue Unlock VRTX Revenue

Net Income

VRTX Net Income Unlock VRTX Revenue

Normalised EPS

VRTX Normalised EPS Unlock VRTX Revenue

PE Ratio Range

VRTX PE Ratio Range Unlock VRTX Revenue

Dividend Yield Range

VRTX Dividend Yield Range Unlock VRTX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
VRTX EPS Forecasts Unlock VRTX Revenue
Profile Summary

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.

Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated January 4, 1989
Public Since July 24, 1991
No. of Shareholders: 1,102
No. of Employees: 3,000
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite , Nasdaq 100 , S&P Composite 1500 , S&P 500 , S&P 500 Health Care (sector),
Exchange NASDAQ Global Select Market
Shares in Issue 260,174,000
Free Float (0.0%)
Eligible for
VRTX Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for VRTX
Upcoming Events for VRTX
Thursday 28th January, 2021 Estimate
Q4 2020 Vertex Pharmaceuticals Inc Earnings Release
Tuesday 27th April, 2021 Estimate
Q1 2021 Vertex Pharmaceuticals Inc Earnings Release
Frequently Asked Questions for Vertex Pharmaceuticals Inc
What is the Vertex Pharmaceuticals Inc share price?

As of 19/01/21, shares in Vertex Pharmaceuticals Inc are trading at $231.91, giving the company a market capitalisation of £44.27bn. This share price information is delayed by 15 minutes.

How has the Vertex Pharmaceuticals Inc share price performed this year?

Shares in Vertex Pharmaceuticals Inc are currently trading at $231.91 and the price has moved by -1.66% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Vertex Pharmaceuticals Inc price has moved by -13.34% over the past year.

What are the analyst and broker recommendations for Vertex Pharmaceuticals Inc?

Of the analysts with advisory recommendations for Vertex Pharmaceuticals Inc, there are there are currently 8 "buy" , 5 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Vertex Pharmaceuticals Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Vertex Pharmaceuticals Inc next release its financial results?

Vertex Pharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Vertex Pharmaceuticals Inc dividend yield?

Vertex Pharmaceuticals Inc does not currently pay a dividend.

Does Vertex Pharmaceuticals Inc pay a dividend?

Vertex Pharmaceuticals Inc does not currently pay a dividend.

When does Vertex Pharmaceuticals Inc next pay dividends?

Vertex Pharmaceuticals Inc does not currently pay a dividend.

How do I buy Vertex Pharmaceuticals Inc shares?

To buy shares in Vertex Pharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Vertex Pharmaceuticals Inc?

Shares in Vertex Pharmaceuticals Inc are currently trading at $231.91, giving the company a market capitalisation of £44.27bn.

Where are Vertex Pharmaceuticals Inc shares listed? Where are Vertex Pharmaceuticals Inc shares listed?

Here are the trading details for Vertex Pharmaceuticals Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: VRTX
What kind of share is Vertex Pharmaceuticals Inc?

Based on an overall assessment of its quality, value and momentum, Vertex Pharmaceuticals Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Vertex Pharmaceuticals Inc share price forecast 2021?

Shares in Vertex Pharmaceuticals Inc are currently priced at $231.91. At that level they are trading at 23.17% discount to the analyst consensus target price of 0.00.

Analysts covering Vertex Pharmaceuticals Inc currently have a consensus Earnings Per Share (EPS) forecast of 10.367 for the next financial year.

How can I tell whether the Vertex Pharmaceuticals Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Vertex Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been -30.43%. At the current price of $231.91, shares in Vertex Pharmaceuticals Inc are trading at -9.91% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Vertex Pharmaceuticals Inc PE Ratio?

The Vertex Pharmaceuticals Inc PE ratio based on its reported earnings over the past 12 months is 22.61. The shares are currently trading at $231.91.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Vertex Pharmaceuticals Inc?

Vertex Pharmaceuticals Inc's management team is headed by:

Bruce Sachs - LED
Amit Sachdev - EVP
Paul Silva - SVP
Jeffrey Leiden - CHM
Terrence Kearney - IND
David Altshuler - EVP
Stuart Arbuckle - EVP
Sangeeta Bhatia - IND
Michael Parini - EVP
Alan Garber - IND
Reshma Kewalramani - PRE
Lloyd Carney - IND
Charles Wagner - CFO
Gerald Bruce - EVP
Carmen Bozic - EVP
Who are the major shareholders of Vertex Pharmaceuticals Inc?

Here are the top five shareholders of Vertex Pharmaceuticals Inc based on the size of their shareholding:

The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 7.96% (20.7m shares)
T. Rowe Price Associates, Inc. Investment Advisor
Percentage owned: 7.83% (20.4m shares)
Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 7.6% (19.8m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 6.32% (16.4m shares)
Capital World Investors Investment Advisor
Percentage owned: 4.37% (11.4m shares)
Similar to VRTX
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.